Associate Professor, Department of Medicine (Hematology/Oncology), UCSF
Additional Websites
Education
Brown University, Providence, RI, Sc.B., 1991, Applied Mathematics/Biology
Johns Hopkins School of Medicine, Baltimore, MD, M.D., 1995, Medicine
Board certified, Internal Medicine, 1998
Board certified, Medical Oncology, 2002
Professional Experience
- 1995-1996
Beth Israel Hospital (Boston, MA), intern, Department of Internal Medicine
- 1996-1998
Beth Israel Hospital (Boston, MA), resident, Department of Internal Medicine
- 1998-2001
Stanford University School of Medicine, fellow, Division of Medical Oncology
- 2001-present
University of California at San Francisco, Clinical Instructor, Division of Hematology/Oncology
- 2003-2009
University of California at San Francisco, Assistant Clinical Professor, Division of Hematology/Oncology
- 2009-present
University of California at San Francisco, Associate Professor of Clinical Medicine, Division of Hematology/ Oncology
Honors & Awards
- 1987
National Merit Scholarship - 1988
IBM Thomas J. Watson Memorial Scholarship - 1990
Sigma Xi, elected associate member - 1991
Departmental honors and Magna cum laude, Brown University - 1993
Alpha Omega Alpha, student essay competition honoree - 1994
Harry C. Saltzstein Prize in Medical Writing, Johns Hopkins School of Medicine - 1995
Medical Assistance Programs/Reader's Digest International Fellowship - 2000
Amgen National Oncology Fellows' Forum, selected for oral presentation - 2000
American Society of Clinical Oncology, Travel Award (meritorious abstract) - 2001
Digestive Disease Center Collaborative Postdoctoral Fellowship - 2003
UCSF Cancer Center Clinical Investigator Research Program award - 2003
American Society of Clinical Oncology Career Development Award - 2007
Joan Rombauer UCSF Endowed Fellowship - 2008
UCSF Kaiser Award for Excellence in Teaching in the Classroom Setting, nominee
Selected Publications
- Ko AH, Cella D. Achieving the best of both worlds. J Clin Oncol. 2013 Jan 1; 31(1):3-4.
View on PubMed - Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol. 2012 Oct; 35(5):411-7.
View on PubMed - Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, Tempero MA. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2012 Dec; 70(6):875-81.
View on PubMed - Morton R, Lucas TH, Ko A, Browd SR, Ellenbogen RG, Chesnut RM. Intracerebral abscess associated with the Camino intracranial pressure monitor: case report and review of the literature. Neurosurgery. 2012 Jul; 71(1):E193-8.
View on PubMed - Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2012 Jun 1; 10(6):703-13.
View on PubMed - Cho EH, Wendel M, Luttgen M, Yoshioka C, Marrinucci D, Lazar D, Schram E, Nieva J, Bazhenova L, Morgan A, Ko AH, Korn WM, Kolatkar A, Bethel K, Kuhn P. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys Biol. 2012 Feb; 9(1):016001.
View on PubMed - Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F, Voigt K, Lazar D, Nieva J, Bazhenova L, Ko AH, Korn WM, Schram E, Coward M, Yang X, Metzner T, Lamy R, Honnatti M, Yoshioka C, Kunken J, Petrova Y, Sok D, Nelson D, Kuhn P. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol. 2012 Feb; 9(1):016003.
View on PubMed - Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, Janne PA, Ko AH, Masters GA, Odenike O, Patel JD, Roth BJ, Samlowski WE, Seidman AD, Tap WD, Temel JS, Von Roenn JH, Kris MG. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol. 2012 Jan 1; 30(1):88-109.
View on PubMed - Ko AH. FOLFIRINOX: a small step or a great leap forward? J Clin Oncol. 2011 Oct 1; 29(28):3727-9.
View on PubMed - Ko AH, Youssoufian H, Gurtler J, Dicke K, Kayaleh O, Lenz HJ, Keaton M, Katz T, Ballal S, Rowinsky EK. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Invest New Drugs. 2012 Aug; 30(4):1597-606.
View on PubMed - Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011 Apr; 17(4):500-3.
View on PubMed - Gordan JD, Chay WY, Kelley RK, Ko AH, Choo SP, Venook AP. "And what other medications are you taking?". J Clin Oncol. 2011 Apr 10; 29(11):e288-91.
View on PubMed - Ko AH, Crane CH. Radiation therapy in operable and locally advanced pancreatic cancer. J Natl Compr Canc Netw. 2010 Sep; 8(9):1022-31.
View on PubMed - Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1051-7.
View on PubMed - Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 1; 15(17):5569-75.
View on PubMed - Ko AH, Tempero MA. Personalized medicine for pancreatic cancer: a step in the right direction. Gastroenterology. 2009 Jan; 136(1):43-5.
View on PubMed - Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas. 2008 Oct; 37(3):269-74.
View on PubMed - Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs. 2008 Oct; 26(5):463-71.
View on PubMed - Kelley RK, Ko AH. Erlotinib in the treatment of advanced pancreatic cancer. Biologics. 2008 Mar; 2(1):83-95.
View on PubMed - Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest. 2008 Feb; 26(1):47-52.
View on PubMed
View on UCSF Profiles
